<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25071143</PMID>
<DateCompleted>
<Year>2014</Year>
<Month>12</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1527-7755</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>32</Volume>
<Issue>24</Issue>
<PubDate>
<Year>2014</Year>
<Month>Aug</Month>
<Day>20</Day>
</PubDate>
</JournalIssue>
<Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
<ISOAbbreviation>J. Clin. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Multiple myeloma in the older adult: better prospects, more challenges.</ArticleTitle>
<Pagination>
<MedlinePgn>2531-40</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Multiple myeloma (MM) is disproportionately diagnosed in older adults; with the aging of the population, the number of older adults diagnosed with MM will increase by nearly 80% in the next two decades. Duration of survival has improved dramatically over the last 20 years, but the improvements in older adults have not been as great as those in younger adults with MM.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">In this article, we address treatment approaches in older adults who are eligible for and those ineligible for high-dose therapy with autologous stem-cell transplantation as well as supportive care considerations and the potential role for geriatric assessment in facilitating decision making for older adults with MM.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The evidence from recent studies demonstrates that combinations of novel and conventional antimyeloma agents result in improved response rates and, in some cases, improved progression-free and overall survival. However, some older adults are particularly vulnerable to toxicities of therapy and discontinuation of therapy and, consequently, they have poorer survival. In addition, older adults may prioritize other outcomes of therapy, such as quality of life, over more conventional end points such as disease response and duration of survival. Geriatric assessment can facilitate risk-stratification of older adults at greater risk for adverse events from therapy and aid in personalizing therapy for vulnerable or frail older adults.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Survival in older adults with MM is improving with novel therapeutics, but efficacy must be balanced with risk of toxicity of therapy and maintenance of quality of life. Novel instruments such as geriatric assessment tools may facilitate these aims.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wildes</LastName>
<ForeName>Tanya M</ForeName>
<Initials>TM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rosko</LastName>
<ForeName>Ashley</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tuchman</LastName>
<ForeName>Sascha A</ForeName>
<Initials>SA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>K12 CA167540</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>UL1 TR000448</GrantID>
<Acronym>TR</Acronym>
<Agency>NCATS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>1K12CA167540</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Clin Oncol</MedlineTA>
<NlmUniqueID>8309333</NlmUniqueID>
<ISSNLinking>0732-183X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009101">Multiple Myeloma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2014</Year>
<Month>7</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2014</Year>
<Month>7</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2014</Year>
<Month>12</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">25071143</ArticleId>
<ArticleId IdType="pii">JCO.2014.55.1028</ArticleId>
<ArticleId IdType="doi">10.1200/JCO.2014.55.1028</ArticleId>
<ArticleId IdType="pmc">PMC4129503</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Ann Oncol. 2007 Aug;18(8):1314-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17631561</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Am Geriatr Soc. 2006 Jun;54(6):925-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16776787</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2011 Sep 1;29(25):3457-65</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21810685</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biol Blood Marrow Transplant. 2013 Jul;19(7):1116-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23660172</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Haematologica. 2013 Jun;98(6):980-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23445873</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2010 Jul 1;28(19):3160-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20516439</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2005 Oct 1;23(28):6865-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16192578</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Haematol. 2003 Feb;120(3):413-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12580955</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Gen Intern Med. 2011 Jul;26(7):783-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21286840</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 1996 Apr;14(4):1327-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8648391</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 1998 Apr;16(4):1582-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9552069</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2012 May 20;30(15):1829-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22508806</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Haematologica. 2013 Jan;98(1):87-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22875621</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncologist. 2011;16(11):1600-3</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21968047</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bone Marrow Transplant. 2003 Dec;32(12):1135-43</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14647267</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Leuk Lymphoma. 2014 Jul;55(7):1489-97</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24144308</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2010 Oct;11(10):934-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20739218</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Health Econ. 2011 Jun;12(3):193-203</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20107856</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Transplant Proc. 2011 Jan-Feb;43(1):244-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21335198</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Haematol. 2010 Jun;84(6):474-83</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20331733</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Apher. 2004;19(4):202-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15597345</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bone Marrow Transplant. 2006 May;37(10):917-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16670701</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2011 Aug 4;118(5):1239-47</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21670471</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Haematologica. 2013 Jul;98(7):997-1000</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23813644</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2009 Aug 1;27(22):3664-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19451428</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2012 May 10;119(19):4375-82</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22422823</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Hematol. 2013 Dec;88(12):1017-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23907769</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Hematol. 2008 Aug;83(8):614-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18429054</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2003 May 8;348(19):1875-83</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12736280</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):541-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23810244</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2010 Jan;11(1):29-37</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19853510</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2012 May 10;366(19):1759-69</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22571200</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2002 Apr 4;346(14):1061-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11932474</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bone Marrow Transplant. 2006 Apr;37(8):731-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16501593</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2010 Aug 5;116(5):679-86</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20385792</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2008 Apr 15;111(8):4039-47</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18268097</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2006 Mar 11;367(9513):825-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16530576</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2009 Apr 9;113(15):3435-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18955563</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bone Marrow Transplant. 2007 May;39(10):605-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17369867</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hematol Oncol Stem Cell Ther. 2011;4(1):30-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21460604</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2010 Dec 1;28(34):5101-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20940200</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2007 Oct 6;370(9594):1209-18</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17920916</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2008 Mar 1;111(5):2521-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17901246</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Leuk Lymphoma. 2012 Jan;53(1):118-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21780997</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 1998 Dec;16(12):3832-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9850028</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2007 May 10;25(14):1824-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17488980</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2009 Jun 10;27(17):2758-65</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19403886</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Leukemia. 2011 Apr;25(4):689-96</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21233832</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bone Marrow Transplant. 2005 Jan;35(2):159-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15543200</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Cancer. 2002 Jul;38(11):1466-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12110492</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Cancer. 2010 Jan;46(1):160-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19682891</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2012 Aug 30;120(9):1801-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22665938</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2008 Aug 28;359(9):906-17</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18753647</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Haematol. 2006 May;133(4):389-96</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16643445</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2011 Oct 27;118(17):4519-29</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21841166</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2003 Dec 25;349(26):2495-502</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14695409</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bone Marrow Transplant. 2003 Feb;31(3):163-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12621476</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2002 Jan 15;20(2):494-502</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11786579</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mayo Clin Proc. 2010 Mar;85(3):225-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20194150</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2010 Apr 22;115(16):3416-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20413666</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bone Marrow Transplant. 2010 Aug;45(8):1259-68</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20479713</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Intern Med. 2013;52(1):63-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23291675</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Geriatr Oncol. 2012 Jul;3(3):279-290</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23024730</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Hematol. 2010 Mar;89(3):317-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19693499</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 2012 Jul 1;118(13):3377-86</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22072065</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2013 Aug 1;31(22):2806-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23796999</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Leukemia. 2014 May;28(5):1122-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24157580</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2008 Mar 1;111(5):2516-20</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17975015</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2004 Dec 15;22(24):4907-17</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15520054</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biol Blood Marrow Transplant. 2008 Sep;14(9):1039-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18721767</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2011 Mar 17;117(11):3025-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21228328</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2013 Jun 1;31(16):1984-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23569317</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>